Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Z. Wang
Observed name:
Zhen Wang
Institutions:
Shandong Tumor Hospital,
Shandong First Medical University
Observed institutions:
Chinese Academy of Medical Sciences & Peking Union Medical College,
Fudan University Shanghai Cancer Center,
Shandong Tumor Hospital,
Jiangsu Province Hospital,
Shandong First Medical University,
State Key Laboratory of Molecular Oncology
show all 6
ORCID:
0009-0006-5643-6112
Observed ORCID:
0009-0006-5643-6112
OpenAlex ID:
A5018320041
1692P A phase Ib/IIa trial to evaluate the safety and efficacy of PM8002/ BNT327, a bispecific antibody targeting PD-L1 and VEGF-A, as a monotherapy in patients with advanced renal cell carcinoma
2024
·
X. Sheng
, H. Luo
, et al.
·
Annals of Oncology
·
6
PDF
The prognostic role of an optimal machine learning model based on clinical available indicators in HCC patients
2024
·
X. Lou
, S. Ma
, et al.
·
Clinica Chimica Acta
·
2
EP08.01-071 Safety and Efficacy of Sitravatinib + Tislelizumab in Patients with PD-L1+, Locally Advanced/Metastatic, Non-Squamous NSCLC
2022
·
J. Zhao
, J. Wu
, et al.
·
Journal of Thoracic Oncology
·
2
PDF
Predicting hormone receptor status in tumors: An innovative approach using breast ultrasound-radiomics combined model
2026
·
Xue Yin
, Zhen Wang
, et al.
·
Medicine
·
1
809MO Efficacy and safety results from the phase II study of Timdarpacept in combination with tislelizumab, in prior anti-PD-1 failed classical Hodgkin lymphoma
2024
·
Y. Song
, K. Zhou
, et al.
·
Annals of Oncology
·
1
PDF
1640P Development and validation of a machine learning-based risk model for metastatic disease in nmCRPC patients
2024
·
Z. Wang
, X. Ni
, et al.
·
Annals of Oncology
·
1
EP08.01-070 Safety and Efficacy of Sitravatinib + Tislelizumab in Patients with PD-L1+, Locally Advanced/Metastatic, Squamous NSCLC
2022
·
J. Zhao
, J. Cui
, et al.
·
Journal of Thoracic Oncology
·
1
Show more works
View as search
Works count:
8
Citation count:
20
H-index:
2
I10-index:
Year
Topic
Type